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We  report an exceptional case of a very late local failure in a 9-year-old boy presenting with
a  chordoma of the cranio-cervical junction. The child was initially treated with a combi-





aggressive therapy allowed a 9-year remission with minimal side-effects. Unfortunately,
he  subsequently presented with a local failure managed with a second full-dose course of
protons. The child died one year later from local bleeding of unclear etiology.
©  2015 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
base (SB) (35%), and the intermediate spinal (S) regions (15%).1.  Introduction
Chordomas (CH) are rare low grade malignancies that rep-
resent approximately 1% of all intra cranial tumors and
4% of bony primaries.1–3 They develop from notochordal
embryonic residues,4 an origin supported by the association
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and).
Only 5% of cases have been described in the pediatric age,
with unclear specificities concerning presentation, and out-
come. We report in this paper a clinical case of skull base CH
Sp. z o.o. All rights reserved.









































Fig. 2 – Same patient as Fig. 1. MRI  aspect at 84 months
follow-up, showing radiotherapy-related bony alterations atreports of practical oncology and 
n a child, and we summarize through the English literature
eculiarities of CH in this age group.
.  Case  report
ntonio M.,  a 9-year-old boy, was referred to the Department
f Neurosurgery in San Giovanni Rotondo (Italy), following
 couple of month-history of posterior cervical pains. On
RI, an extensive tumor process was visualized. It extended
rom the lower clivus, through the foramen magnum,  down
o C2, inclusive. The tumor was abutting the medulla and
ervical cord anteriorly and laterally, right side. It extended
ubstantially in the soft tissues anteriorly, with a visible
rotrusion, on physical examination, through the poste-
ior aspect of the nasopharynx. Estimated dimensions were
5 mm × 15 mm.  The child was operated on through two suc-
essive approaches, in March and April 2000. The tumor
ed was filled with fatty and muscular tissue. Pathological
xamination was consistent with a CH. On histopathologi-
al study, the tumor was positive for epithelial (KL1+, EMA+),
nd mesenchymal (PS100) antigens. Post-operative MRI was
f a difficult interpretation, due to the interposition of soft
issue although multiple small residual foci were suspected
ithin the canal. The patient was referred to the Institut
ustave-Roussy, in Villejuif (France) where high dose, high
recision post-operative radiotherapy was recommended. A
ombined photon–protontherapy program was implemented
n collaboration with the Institut Curie-Proton Therapy Cen-
er, in Orsay (ICPO, France). It delivered, from January 2001
hrough March 2001, a total of 68.4 Gy (RBE) in 5 daily frac-
ions of 1.8 Gy each per week (Gy (RBE) corresponds to the
hysical dose times an estimated 1.1 mean RBE value). Half
as delivered using 3D conformal 15 MV  photons, and half
sing 201 MeV  protons, with a fixed horizontal beam, on a pas-
ive scattering mode (Fig. 1). Acute tolerance was satisfactory
ith mild headaches, nauseas, and mucositis, managed with a
hort course of steroids and mouthwash. Follow-up was alter-
ated between France and Italy and uneventful until January
ig. 1 – 9 year-old boy with skull base-cervical canal
hordoma. Post-operative photon-proton radiotherapy
id-plane dose-distribution. Prescribed dose: 68.4 Gy (RBE)
personal coll.).C1-C2 (personal coll.).
2010. At that time, 106 months following radiotherapy, per-
formance status was excellent, with only a slight permanent
neck deviation, related with mild radiation-induced atrophy
of C1, and of the occipital bone (Fig. 2). C1 deformation was
attributed retrospectively to left to right vertebral body dose-
gradient that ranged between 9 and 48 Gy. Unfortunately, MRI
also evidenced a local tumor progression along the pharyn-
geal wall. A grossly subtotal resection was performed abroad
in the same neurosurgical department, in May 2010, followed
by a second course of conventionally fractionated protons,
at ICPO, up to 70 Gy (RBE) (Fig. 3). The cumulative biologi-
cally equivalent dose (BED) was estimated retrospectively to
165 Gy10 for tumor, and 270 Gy2 for late CNS  reactions. These
theoretical estimates do not take into account the extensive
delay between treatments. The patient could resume normal
Fig. 3 – Same patient as Fig. 1. Re-irradiation for local failure
at 106 months. Prescribed dose: 70.2 Gy (RBE) (personal coll.).
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life for almost a year, when a cataclysmic hemorrhage was
exteriorized through the mouth. Despite his referral to the
emergency unit of the local hospital, the patient died shortly
thereafter. No autopsy was performed. It was impossible ret-
rospectively to assess whether the cause of death was tumor
progression, radionecrosis of the internal carotid artery or of
one of its branches, or a combination of both.
3.  Review  of  literature
Cranial CH is a very rare entity in the pediatric population,
since it represents less than 1% of intra cranial malignan-
cies and 5% of all CHs.7–9 Mean age varies according to series
between 8 and 12 years, most approaching 10 years.10,11 There
are case-reports of newborns affected with CHs.12 Sex ratio
is close to 1, although some series evidence a slight female
predominance.13,14 Several factors differ between adults and
children at presentation, and following therapy. They con-
cern anatomical sites, extension, tolerance to therapy, and
outcome.
As far as anatomical sites are concerned, several authors
have evidenced that the proportion of lower sites was inferior
in children compared with adults: SB: 54% vs. 35%; S: 23% vs.
15% and SC: 22% vs. 50%.7,11,14 But this proportion seems supe-
rior in younger children, which could explain, in part, a worse
outcome.15,16 Interestingly, multiple reports concern unusual
presentations in youngsters, such as: extra clival cranial, intra
cerebral, mediastinal, gluteal, etc.17–29
Symptoms at presentation depend on the tumor site, and
are not specific to children. If they are IC, cranial nerve palsies
are seen in 60% or so.10,30 Non specific symptoms of hydro-
cephalus are present in one-third of cases.31 Cervical-S sites or
extension include also frequently stiff neck and nasal obstruc-
tion. Physical examination is generally positive for a retro
pharyngeal mass. SC sites are frequently revealed by pains in
the lower back, associated or not with a sacral mass when the
tumor is located posteriorly; when the lesion extends anteri-
orly, diagnosis is frequently late and revealed by symptoms of
digestive or cauda equina compression.32–34
As for metastases, they are rare at presentation in all age-
groups (<5%, except SC ≤25%).11,14,30,35 Dissemination within
the CNS, similar to the natural history of medulloblastomas,
has been exceptionally reported.36 Many  practitioners with
limited experience in this tumor type point out to their
patients that CH is a benign process. Metastases are more
common in the course of the disease with a pediatric predom-
inance compared with adults: 9–58% range vs. 7–40%.10,31,37 In
these situations, they are frequently associated with a local
failure.38 Some patterns of such “combined” failures are more
frequently reported such as local + nodal or local + surgical
route. Distant metastases are mainly pulmonary.31,37 This pat-
tern has been correlated with a higher proportion of atypical
pathological variants compared with adults especially those
<5 years of age (approx 65% vs. 20%). This age group is also
remarkable for a higher proportion of SC sites (25% vs. 6%),
compared with older children. The worse prognosis associ-
ated with SC sites could be correlated with the density of the
venous drainage in this anatomical region. Associated morbid
conditions have also been reported in a very early childhood:iotherapy 2 1 ( 2 0 1 6 ) 412–417
among them, the tuberous sclerosis is a neurofibromatosis
associated with benign and malignant primaries. These con-
ditions have been associated with tyrosine kinase pathways
impairments, including anomalies of the mTOR  pathway,
responsible for uncontrolled cellular proliferation.2,39–41 Epi-
dermal growth factors inhibitors and mTOR  inhibitors have
been tested with remarkable but transient responses in both
recurrent and metastatic presentations (see below).
Treatment strategy is common with that in adults: maxi-
mal  surgical resection followed by high-dose, high-precision
radiation therapy. Children must be operated on by pediatric
surgical teams with experience in SB and S management.
Multidisciplinary teams (neurosurgical, otolaryngological,
orthopedic) are frequently mobilized for such sophisticated
approaches, through national, and international collabora-
tions. Multiple successive procedures are routinely requested
for SB CH: through anterior (trans oral, trans palatine), poste-
rior, and lateral approaches. The extension down through the
foramen magnum needs a separate, generally anterior-lateral
approach. Quality of resection based on modern imaging tech-
niques (MRI, neuronavigation, endoscopy) and on modern
surgical techniques (laser, microsurgery) has been substan-
tially improved, but incomplete resection remains frequent
in children: 0–36% in literature.7,11,30,35 Metallic fixations can
be requested for spinal consolidation. As they call for metal-
lic material (rods, screws, cages) they can pose additional
challenges to particle therapy, both at the time of simulation
(requesting a MV CT simulator), and in treatment (multiple
beam-angle restrictions, related with potential alterations of
the particles path).
While a complete surgical resection remains crucial for
long term local control,42 the difficulties at performing a
complete surgical resection have stimulated the interest in
additional radiation therapy.43 CH has the reputation of a
highly radio-resistant process that is confirmed by disappoint-
ing outcome of a series dealing with 2D and 3D conventionally
fractionated photon therapy: 17–40% long term survivors, fol-
lowing doses ≤55–60 Gy.44 Results with stereotactic mono or
pauci fractionated photon therapy have also been brought
out with interesting results in highly selected patients.44 The
introduction of high dose, high precision protontherapy in
the mid-seventies at Massachusetts General Hospital, Boston,
turned out to be a breakthrough, with approximately two-third
of patients remaining alive with NED at 3–4 years in SB, and
cervical-S locations.45 This favorable outcome has been repro-
duced by multiple teams in US, Europe and Japan.46–48 Doses
were progressively upgraded to 75 Gy (EBR) (Gy (EBR) = physical
dose × an estimated mean 1.1 RBE) and more,  conventionally
fractionated, at the price of an acceptable toxicity. Recently,
carbon ions have also been advocated in place of protons.42,49
In children, the combination of surgery and radiotherapy
is also recommended,50,51 with no dose-alteration, despite
the increased risks of severe side-effects following higher
doses.52 But dose adaptations can be proposed according to
age, patient’s conditions, and size of the residues.
In children, long term risks can be conveniently stratified
in two groups, whether 1 – they are shared with adults at
approximately the same dose-levels, or 2 – are observed at
significantly different dose levels or totally unrelated: the first
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upra tentorium (esp. temporal lobes, close to the skull base),
nfra tentorium (brain stem, and cerebellum), spinal cord, and
ranial neuropathies (rather uncommon, except for the II and
III nerves). The second group is represented by: pituitary
ailure affecting growth hormone and spurt, cognitive impair-
ents related with the inclusion of large white matter sectors,
r of sensitive structures such as hippocampus; bone and car-
ilage plates growth delays inducing shortening of long bones,
acial deformities, etc. In this group, a dose gap between adults
nd children is also correlated with younger age at therapy.
s a rule, dose range associated with damages is inferior to
urative doses recently recommended in CHs (i.e. 70–75 Gy
ractionated, total dose). We will mention brain and spinal
ord necrosis >55 Gy and >48 Gy respectively, in the first group
approx. 5% risk at 5 years, both in adults and children). But the
ost challenging situations concern the organs, and physio-
ogic functions pertaining to the second group; cartilage arrest
15 Gy, and GH pituitary hormone failure >25 Gy, in children.
oncomitant chemotherapy can further alter radiation toler-
nce. If tolerance of the second group organs remains a major
oncern (high frequency of pituitary hormones replacement,
nd cosmetic deformities, such as in our own case), tolerance
f the first group organs is not trivial (substantial risk of inter-
al auditory failure).
In adults, high-dose high-precision proton-based radio-
herapy yields a long term disease-free survival (or local
ontrol) and overall survival between 55–87%, and 55–94%,
espectively.45–48,51,53 Pediatric CHs seem to fare better com-
ared with their adult counterparts: 60–100% and 80–100%,
espectively.13,30,50,54,55 Nonetheless, younger children were
requently excluded in earlier series dealing with protons
since they require special attention, such as general anesthe-
ia). Younger patients (i.e. <5 years of age) behave actually less
avorably.10,11,31,37,54 This seems to be related with a higher
ate of undifferentiated histologies, and a more rapid pace
f the disease, related with upfront or secondary metas-
ases. These tumors are also more  frequently located in
he SC region with frequent advanced presentation that
ose highly challenging surgical decisions (especially in case
f S3 invasion). Furthermore, unlike the adults, the chon-
roid subtype does not seem to have a favorable impact on
rognosis.7,56
In the case of a local-regional failure, re-irradiation is
ncreasingly considered a reasonable option, especially in the
ontext of modern technologies. It still remains complex due
o the subtle balance between a tumor dose level associated
ith a prolonged local control expectancy and a relatively
afe dose to critical organs. This concept deals with poorly
ocumented factors, especially alterations of tumor cells and
icro-environment radiosensitivity following a second course
f irradiation, and influence of delay between both courses.
ose fractionation and target volume are also important to
onsider. In a Canadian survey, most radiation oncologists
ept away from CNS primaries re-irradiation, and recom-
ended low-dose conventionally fractionated regimes (i.e.
0 Gy in 10 fractions).57 For Ang, based on spinal cord exper-
ments on a monkey, a three year-delay seemed optimal for
ull recovery of radiation injuries following a first course of
4 Gy fractionated, allowing supposedly a full dose adminis-
ration, at second course.58 Expert consensus consider that atherapy 2 1 ( 2 0 1 6 ) 412–417 415
cumulative dose of 90 Gy remains on the safe side, in adults
affected with recurrent gliomas.59 BED is a useful prognos-
ticator of “biological” dose that takes into account cellular
sensitivity (i.e. / value of the linear quadratic survival curve
model), and dose per fraction.59 When / = 2 Gy (a commonly
accepted value for cell populations involved in late responses),
the 2 Gy-equivalent dose (EQ2) equals half that value. In our
case-report, despite a high cumulative BED of 270 Gy2, and
QD2 = 135 Gy (for late responding tissues), we  estimated a 10
year-interval to be sufficient for full recovery of anatomi-
cal critical structures. We  also recommended a stereotactic
approach, based on the use of protons alone, along with
fiducial markers alignment and a minimal target-volume for
re-irradiation based on GTV + 2 mm safety margin or so. This
was supposed to virtually take out all sensitive CNS structures
from the beams’ path.
Chemotherapy is also commonly used in pediatric
malignancies, but episodically only in CHs.7,11,30,60 Poly-
chemotherapy regimens have been administered with drugs
similar to soft part sarcomas (ifosfamide, doxorubicin, etopo-
side), and again mainly indicated where local treatment had
failed previously. Few very young children have been managed
with upfront chemotherapy, due to an extensive presentation
of the disease locally and/or distantly. In adults, targeted ther-
apy has also drawn attention: Imatinib Mesylate, a tyrosin
kinase receptor inhibitor (CKIT), and Sirolimus, an inhibitor of
the MTOR kinase pathway, have been tested in advanced local
or metastatic presentations or as a salvage program at the time
of a failure with documented objective responses. For exam-
ple, in one phase II Italian-Swiss study of 50 patients, median
progression-free survival was 9 months with 64% patients
experiencing a clinical benefit.61–63
4.  Conclusion
Our case represents an exceptionally delayed local failure in
a child affected with a cranio-cervical chordoma. Despite the
excellent outcome reported in the literature in children with
chordomas using high dose high precision particle therapy,
a protracted follow-up in excess of 10 years is warranted.
Following a surgical salvage program, re-irradiation should
be considered a challenging option in the head and neck
region. The BED concept could help define dose-constraints
to the tumor and normal tissues, whereas target volume
should be confined to macroscopic residues only, with no or
minimal safety margins. Alternative approaches combining
sub-optimal radiation doses, along with sensitizing agents, are
also warranted.
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